非ST段抬高型急性冠脉综合征非侵入治疗患者中胃肠外抗凝治疗与结局的关联:CCC项目发现
校正混杂因素后,PACT与院内全因死亡风险降低无关(调整OR 1.25,95%CI 0.92-1.71,P=0.151),也未增加大出血或小出血发生率。倾向性评分分析证实了主要结果。
要点
- 在未行侵入治疗的NSTE-ACS患者中,PACT未降低院内全因死亡风险。
- PACT未显著增加大出血(调整OR 1.04)或小出血(调整OR 1.27)风险。
- 倾向性评分分析结果与主要分析一致,仍需随机临床试验验证。
核心结论
- 在接受非侵入治疗且联用抗血小板药物的NSTE-ACS患者中,PACT与院内全因死亡风险降低无关,也未增加出血风险。
研究设计与样本
- observational cohort study enrolled patients with NSTE-ACS receiving medical therapy from November 2014 to June 2017 in the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome project.
- Among 23,726 patients, 8,845 eligible patients who received medical therapy were enrolled.
主要发现
- PACT was not associated with a lower risk of in-hospital all-cause mortality (adjusted OR 1.25; 95%CI 0.92-1.71; P=0.151).
- PACT did not increase the incidence of major bleeding (adjusted OR 1.04; 95%CI 0.80-1.35; P=0.763) or minor bleeding (adjusted OR 1.27; 95%CI 0.91-1.75; P=0.156).
- The propensity score analysis confirmed the primary analyses.
临床怎么用
- 对于NSTE-ACS接受非侵入治疗并联合抗血小板策略的患者,PACT未显示降低院内全因死亡或增加出血风险,临床决策需个体化权衡。
局限性
- Randomized clinical trials are warranted to reevaluate the safety and efficacy of PACT in all patients with NSTE-ACS who receive noninvasive therapies and current antithrombotic strategies.
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our previous study showed that parenteral anticoagulation therapy (PACT) in the context of aggressive antiplatelet therapy failed to improve clinical outcomes in patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome (NSTE-ACS). However, the role of PACT in patients managed medically remains unknown. This observational cohort study enrolled patients with NSTE-ACS receiving medical therapy from November 2014 to June 2017 in the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome project. Eligible patients were included in the PACT group and non-PACT group. The primary outcomes were in-hospital all-cause mortality and major bleeding. The secondary outcome included minor bleeding. Among 23,726 patients, 8,845 eligible patients who received medical therapy were enrolled. After adjusting the potential confounders, PACT was not associated with a lower risk of in-hospital all-cause mortality (adjusted odds ratio (OR), 1.25; 95% confidence interval (CI), 0.92-1.71; P = 0.151). Additionally, PACT did not increase the incidence of major bleeding or minor bleeding (major bleeding: adjusted OR, 1.04; 95% CI, 0.80-1.35; P = 0.763; minor bleeding: adjusted OR, 1.27; 95% CI, 0.91-1.75; P = 0.156). The propensity score analysis confirmed the primary analyses. In patients with NSTE-ACS receiving antiplatelet therapy, PACT was not associated with a lower risk of in-hospital all-cause mortality or a higher bleeding risk in patients with NSTE-ACS receiving non-invasive therapies and concurrent antiplatelet strategies. Randomized clinical trials are warranted to reevaluate the safety and efficacy of PACT in all patients with NSTE-ACS who receive noninvasive therapies and current antithrombotic strategies.
引用
- Liu YH, Fan HL, Zeng LH, et al. Association of Parenteral Anticoagulation Therapy With Outcomes in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Without Invasive Therapy: Findings from the Improving Care for Cardiovascular Disease in China (CCC) project. Clin Pharmacol Ther. 2021. PMID: 34287856. doi:10.1002/cpt.2370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。